D. Boral Capital Reiterates Buy Rating for Hoth Therapeutics (NASDAQ:HOTH)

Hoth Therapeutics (NASDAQ:HOTH)‘s stock had its “buy” rating reaffirmed by equities research analysts at D. Boral Capital in a research note issued on Tuesday,Benzinga reports. They presently have a $5.00 price target on the stock. D. Boral Capital’s price objective points to a potential upside of 397.51% from the company’s previous close.

Separately, HC Wainwright restated a “buy” rating and set a $4.00 price target on shares of Hoth Therapeutics in a research report on Thursday, January 23rd.

Hoth Therapeutics Stock Up 15.5 %

Shares of HOTH stock traded up $0.14 during trading on Tuesday, hitting $1.01. The company had a trading volume of 3,701,825 shares, compared to its average volume of 12,814,855. The stock’s 50-day moving average is $1.19 and its two-hundred day moving average is $0.98. The stock has a market capitalization of $6.94 million, a price-to-earnings ratio of -0.76 and a beta of 0.80. Hoth Therapeutics has a 52 week low of $0.58 and a 52 week high of $3.80.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Hoth Therapeutics stock. Virtu Financial LLC purchased a new stake in shares of Hoth Therapeutics, Inc. (NASDAQ:HOTH) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 32,636 shares of the company’s stock, valued at approximately $29,000. Virtu Financial LLC owned 0.47% of Hoth Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 7.08% of the company’s stock.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.